Flightpath Biosciences

Flightpath Biosciences is pioneering a precision anti-infective approach to treat complex, infection-driven diseases by selectively deleting harmful bacteria without disrupting the commensal microbiome. Its core platform, Targeted Bacterial Deletion™, is being applied to a diverse pipeline targeting pathogens implicated in colorectal cancer, periodontal disease, inflammatory bowel disease, Lyme disease, bacterial vaginosis, and endometriosis. The company is in a pre-clinical to early clinical stage, having recently in-licensed assets to accelerate its pipeline, and operates as a private entity. Its strategy addresses the growing understanding of the microbiome's role in chronic inflammation, cancer, and systemic health.

Targeted Bacterial Deletion™ - a proprietary platform designed to selectively remove harmful gram-negative bacteria that drive complex diseases, without negatively impacting the surrounding healthy microbiome.

Flightpath competes in the emerging field of precision anti-infectives and microbiome modulation. While broad-spectrum antibiotics are the standard of care, they are not competitors for this niche. Direct competition comes from other biotechs developing targeted antimicrobials or live biotherapeutics, but the specific focus on gram-negative 'keystone pathogens' across systemic diseases is a differentiating strategy.